FAST NEWS: Genscript’s new cancer drug sales surge in third quarter
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday that sales of its Carvykti cancer drug jumped 176% to $152 million in the third quarter…
FAST NEWS: Legend Biotech shares jump on rising cancer drug sales
The latest: Cell therapy company Legend Biotech Corp. (LEGN.US) recorded net sales of $117 million in the second quarter for its Carvykti cancer drug, up 65% from the previous quarter, according to…
FAST NEWS: Legend Biotech cancer drug posts strong first-quarter sales
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday it recorded net sales of approximately $72 million in the first quarter for its Carvykti cancer…
FAST NEWS: Legend Biotech Plans $250 Million ADS Public Offering
The latest: Genscript Biotech Corp. (1548.HK) announced its New York-listed subsidiary, Legend Biotech Corp. (LEGN.US), plans to conduct a public offering of $250 million worth of American Depository Shares (ADS).…
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
Company expects to lose up to $519 million last year, but its fortunes may improve after its Legend Biotech unit received FDA approval this week for a new CAR-T cell…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
